Abcam (OTCMKTS:ABCZY) is a global life sciences company headquartered in Cambridge, UK. Founded in 1998, the company specializes in the development and distribution of high-quality protein research tools and services. Abcam’s portfolio encompasses primary and secondary antibodies, immunoassays, recombinant proteins, peptides and gene editing reagents, supporting a wide range of applications in biomedical research.
The company offers an extensive catalog of over 200,000 products, delivered to scientists worldwide through e-commerce platforms and a network of distribution partners. Abcam’s digital-first approach includes an online platform that integrates advanced search, data sharing and customer support features to streamline reagent selection, ordering and data management for research professionals.
Serving academic institutions, biotechnology firms and pharmaceutical companies, Abcam’s offerings facilitate target validation, biomarker discovery, drug development and diagnostic assay design. With operations across North America, Europe and Asia-Pacific, the company maintains R&D centers and manufacturing facilities to ensure local supply and regulatory compliance in key markets.
Led by founder and executive chairman Jonathan Milner, Abcam’s management team brings deep expertise in biotechnology, protein science and global commercialization. The company has pursued strategic investments and acquisitions to expand its capabilities in proteomics, genomics and assay development, underscoring its commitment to innovation and customer collaboration in the life sciences sector.
AI Generated. May Contain Errors.
